Ardelyx Inc
ARDX4.330USD
0.0000.00%
收盘 08/01, 16:00（美东）报价延迟15分钟
1.04B总市值
亏损市盈率 TTM
关于 Ardelyx Inc 公司
Ardelyx, Inc. 是一家生物制药公司。该公司专注于发现、开发和商业化满足重大未满足医疗需求的先进药物。它有两种商业产品 IBSRELA（tenapanor）和 XPHOZAH。其产品线包括 RDX013 计划和 RDX020 计划。Tenapanor 是一种正在开发的小分子疗法，用于治疗或控制透析成年慢性肾病 (CKD) 患者的高磷血症或血清磷。Tenapanor 具有作用机制，在肠道局部作用以抑制钠氢交换器 3 (NHE3)。IBSRELA 是为治疗便秘型肠易激综合征 (IBS-C) 患者而开发的。XPHOZAH 是一种用于控制透析成年 CKD 患者血清磷的药物。RDX013 计划是一种用于治疗高钾血症的小分子钾促泌剂计划。 RDX020 计划是一种用于治疗代谢性酸中毒的小分子。
公司简介
公司代码ARDX
公司名称Ardelyx Inc
上市日期Jun 19, 2014
CEOMr. Michael G. (Mike) Raab
员工数量395
证券类型Ordinary Share
年结日Jun 19
公司地址400 Fifth Avenue
城市WALTHAM
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02451
电话15107451700
网址https://www.ardelyx.com/
公司代码ARDX
上市日期Jun 19, 2014
CEOMr. Michael G. (Mike) Raab
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
477.14K
-12.42%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
314.17K
-0.79%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
137.35K
+43.37%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
41.55K
--
James Brady
James Brady
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Merdad Parsey, M.D., Ph.D.
Dr. Merdad Parsey, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Mike Kelliher
Mr. Mike Kelliher
Chief Business Officer
Chief Business Officer
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
2.86M
+19.80%
Mr. Michael G. (Mike) Raab
Mr. Michael G. (Mike) Raab
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
477.14K
-12.42%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
413.54K
+17.98%
Mr. Eric Foster
Mr. Eric Foster
Chief Commercial Officer
Chief Commercial Officer
314.17K
-0.79%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
137.35K
+43.37%
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Independent Director
Independent Director
41.55K
--
收入明细
FY2025Q1
FY2024
FY2024Q2
FY2024Q1
业务USD
名称
营收
占比
IBSRELA
44.40M
0.00%
XPHOZAH
23.41M
0.00%
暂无数据
业务
地区
业务USD
名称
营收
占比
IBSRELA
44.40M
0.00%
XPHOZAH
23.41M
0.00%
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Janus Henderson Investors
10.44%
The Vanguard Group, Inc.
6.70%
BlackRock Institutional Trust Company, N.A.
6.64%
Millennium Management LLC
5.06%
Macquarie Investment Management
4.66%
Other
66.50%
持股股东
持股股东
占比
Janus Henderson Investors
10.44%
The Vanguard Group, Inc.
6.70%
BlackRock Institutional Trust Company, N.A.
6.64%
Millennium Management LLC
5.06%
Macquarie Investment Management
4.66%
Other
66.50%
股东类型
持股股东
占比
Investment Advisor
27.48%
Investment Advisor/Hedge Fund
26.34%
Hedge Fund
13.49%
Research Firm
4.93%
Individual Investor
2.66%
Bank and Trust
0.37%
Pension Fund
0.36%
Family Office
0.09%
Insurance Company
0.03%
Other
24.24%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
460
181.09M
75.69%
+6.96M
2025Q1
470
173.66M
72.61%
+2.64M
2024Q4
452
158.29M
66.42%
-9.57M
2024Q3
441
149.04M
63.31%
-41.81M
2024Q2
420
152.02M
64.97%
-36.87M
2024Q1
399
149.36M
64.27%
-40.02M
2023Q4
363
143.31M
61.82%
-29.22M
2023Q3
347
131.10M
60.21%
-55.04M
2023Q2
355
129.77M
60.57%
-68.74M
2023Q1
359
119.15M
57.99%
-45.93M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Janus Henderson Investors
24.98M
10.44%
+589.07K
+2.42%
Mar 31, 2025
The Vanguard Group, Inc.
14.94M
6.25%
+634.58K
+4.44%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
15.88M
6.64%
-651.24K
-3.94%
Mar 31, 2025
Millennium Management LLC
12.10M
5.06%
+5.63M
+87.15%
Jun 17, 2025
Macquarie Investment Management
11.16M
4.66%
+811.55K
+7.84%
Mar 31, 2025
State Street Global Advisors (US)
10.18M
4.25%
-1.42M
-12.22%
Mar 31, 2025
Marshall Wace LLP
8.38M
3.5%
+8.27M
+7201.76%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.67M
2.37%
+162.88K
+2.96%
Mar 31, 2025
Nuveen LLC
3.39M
1.42%
+1.24M
+57.47%
Mar 31, 2025
Citadel Advisors LLC
3.19M
1.33%
+699.74K
+28.09%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Products ETF
2.03%
Harbor Human Capital Factor US Small Cap ETF
0.53%
Invesco NASDAQ Future Gen 200 ETF
0.48%
SPDR S&P Biotech ETF
0.36%
Direxion Daily S&P Biotech Bull 3X Shares
0.2%
First Trust Small Cap Growth AlphaDEX Fund
0.18%
Inspire Small/Mid Cap ESG ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
iShares Russell 2000 Growth ETF
0.06%
查看更多
Virtus LifeSci Biotech Products ETF
占比2.03%
Harbor Human Capital Factor US Small Cap ETF
占比0.53%
Invesco NASDAQ Future Gen 200 ETF
占比0.48%
SPDR S&P Biotech ETF
占比0.36%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.2%
First Trust Small Cap Growth AlphaDEX Fund
占比0.18%
Inspire Small/Mid Cap ESG ETF
占比0.16%
Invesco Nasdaq Biotechnology ETF
占比0.1%
ProShares Ultra Nasdaq Biotechnology
占比0.1%
iShares Russell 2000 Growth ETF
占比0.06%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
